Latest Headlines
-
Nikon CeLL Innovation Enters Into A Strategic License Agreement With RoosterBio
4/15/2025
Nikon CeLL innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation has entered into a strategic licensing agreement with RoosterBio, Inc. (RoosterBio), a leading stem cell technology company in the US.
-
Novotech Expands South Korean Presence With New Hospital Trial Site Deal
4/4/2025
Australian CRO Novotech has signed a memorandum of understanding with the Kyungpook National University Hospital (KNUH), furthering its partnership strategy in South Korea.
-
Novotech Named Best Contract Research Organization In Australia At Asia-Pacific Biopharma Excellence Awards 2025
4/3/2025
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market has been recognized as the Best Contract Research Organization in Australia at the Asia-Pacific Biopharma Excellence Awards (ABEA) 2025.
-
Novotech Report Reveals Growth In siRNA Research
4/3/2025
Sydney, March 2025 – Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its newest preclinical report exploring the evolving landscape of small interfering RNA (siRNA) therapeutics. This report provides insights for biotech and pharmaceutical companies leveraging RNA-based precision medicine to develop next-generation treatments for oncology, metabolic disorders, and rare genetic diseases.
- Landmark Bio Acquired By Artis BioSolutions To Expand Manufacturing And Commercialization Of Advanced Therapies 4/2/2025
-
Miltenyi Biotec To Commercially Supply CliniMACS® Platform To Autolus Therapeutics For Its Manufacture Of FDA-Approved AUCATZYL® (Obecabtagene Autoleucel – Obe-Cel)
3/28/2025
Miltenyi Biotec, a global leader innovating technologies and services for patient-specific cell and gene therapies, today announced that it will supply Miltenyi Biotec’s CliniMACS Prodigy® instruments, reagents, and disposables for the manufacture of Autolus’ FDA-approved AUCATZYL® (obecabtagene autoleucel), as part of its longstanding partnership with the CAR T cell therapy developer since 2018.
-
Global Reach For Biotechs: Avance Clinical Secures MOUs With Four Premier Taiwanese Trial Sites
3/24/2025
Avance Clinical, a leading full-service global Contract Research Organization (CRO) specializing in high-quality, agile clinical biotech research services, is pleased to announce the signing of four Memorandums of Understanding (MOUs) with key clinical trial sites in Taiwan this week.
-
Avance Clinical Expands In Asia With Taipei Office To Accelerate Biotech Clinical Trials
3/24/2025
Avance Clinical, the award-winning, full-service Contract Research Organization (CRO) specializing in delivering agile and accelerated clinical development solutions for global biotechs, has further strengthened its presence in Asia with the opening of an office in Taipei, Taiwan.
-
Novotech Partners With Kyungpook National University Hospital To Strengthen Clinical Trial Capabilities In South Korea
3/19/2025
Novotech, a global leading full-service clinical CRO, and Acrostar, a provider of Site Management Organization (SMO) services, have entered into a strategic partnership that will support clinical trials across NHUH’s prestigious institutions including the Advanced Clinical Trials Center, the KNUH main campus, and the Chilgok KNUH in South Korea.
-
Aseptic Filling System Provider Announces New Chief Commercial Officer
3/17/2025
AST, a leading provider of flexible aseptic filling systems, is pleased to announce an exciting addition to the Leadership team. Charisse Curtis has joined AST as Chief Commercial Officer, leading the Business Development, Marketing, and Communications teams.